RCS - Aptamer Group PLC - Investor Webinar

AptamerAnnouncement

08/12/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221208:nRSH9757Ia&default-theme=true

RNS Number : 9757I  Aptamer Group PLC  08 December 2022

08 December 2022

 

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

 

 Investor Webinar

 

Aptamer Group plc (AIM: APTA), the developer of novel Optimer(®) binders to
enable innovation in the life sciences industry, today announces that Dr Arron
Tolley, Chief Executive Officer, Dr David Bunka, Chief Technical Officer and
Jenny Cutler, Interim Chief Financial Officer, will share an update on the
business via the Investor Meet Company platform on 13th Dec 2022 at 2:00pm
GMT. No new information will be disclosed during the event.

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and meet Aptamer
Group via:
https://www.investormeetcompany.com/aptamer-group-plc/register-investor
(https://www.investormeetcompany.com/aptamer-group-plc/register-investor)

Investors who already follow Aptamer Group on the Investor Meet Company
platform will automatically be invited.

 

- ENDS -

 

For further information, please contact:

 

Aptamer Group plc

Dr Arron Tolley
                                       +44 (0) 1904 217
404

Consilium Strategic Communications

Matthew Neal / Chris Welsh / Lucy Featherstone
                +44 (0) 20 3709 5700

aptamergroup@consilium-comms.com (mailto:aptamergroup@consilium-comms.com)

 

About Aptamer Group plc

Aptamer (http://www.aptamergroup.com/) Group develops custom affinity binders
through its proprietary Optimer(®) platform to enable new approaches in
therapeutics, diagnostics and research applications. The Company strives to
deliver transformational solutions that meet the needs of life science
researchers and developers through the use of its proprietary Optimer
platform.

Optimer binders are oligonucleotide affinity ligands that can function as an
antibody alternative. The global antibody market is currently worth over
$145.0 billion. Optimer binders are engineered to address many of the issues
found with alternative affinity molecules, such as antibodies, and offer new,
innovative solutions to bioprocessing, diagnostic and pharmaceutical
scientists.

Aptamer Group has successfully delivered projects for global pharma companies,
diagnostic development companies, and research institutes covering a range of
targets and applications with the objective of establishing royalty-bearing
licenses. Through the unique Optimer technology and processes, scientists and
collaborators are enabled to make faster, more informed decisions that support
discovery and development across the Life Sciences.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFSDFVLDIIF